RHHBF - Illumina Revenue Decline And Other News: The Good Bad And Ugly Of Biopharma
Illumina stock tumbles as quarterly numbers decline
Illumina Inc. (ILMN) reported its second quarter financial results. However, due to various factors including the pandemic outbreak, the numbers were not too good. The company also provided updates about business operations including new appointments and capital expenditures. Illumina has already announced the withdrawal of its fiscal 2020 full-year revenue and earnings per share guidance.
Illumina reported its revenue for the second quarter at $633 million, down 25 percent on a year over year basis. The company had reported $838 million in revenue for the second